Investment Rating - The report maintains a "Strong Buy" rating for Weitai Medical-B (02235.HK) [1] Core Views - The company recently announced a positive earnings forecast for 2025, projecting revenue of no less than 650 million yuan, representing a year-on-year growth of approximately 88.1%, and achieving a net profit of no less than 38 million yuan, reversing a loss of 63 million yuan in the same period last year [1] - Revenue growth is primarily driven by strong performance in core products, particularly Continuous Glucose Monitoring (CGM) systems, and significant expansion in overseas markets [6] - The company has successfully entered multiple countries with its LinX CGM system, leading to substantial international revenue growth [6] - The company is expected to continue high growth in overseas markets in 2026, with recent approvals in populous countries like India and Brazil [6] - The closed-loop artificial pancreas is anticipated to receive approval in 2026, which will enhance the company's diabetes management product portfolio [6] - The target market capitalization is set at 5.9 billion HKD, corresponding to a target price of 14.0 HKD per share, based on a 4x PS valuation for the main business [6] Financial Summary - Total revenue projections for 2025-2027 are 651 million, 882 million, and 1,161 million yuan, with year-on-year growth rates of 88.3%, 35.6%, and 31.6% respectively [6] - Net profit projections for the same period are 38 million, 93 million, and 152 million yuan, with year-on-year growth rates of 160.7%, 143.2%, and 63.5% respectively [6] - The company has a total market capitalization of 3.196 billion HKD and a circulating market value of 1.257 billion HKD [3]

Investment Rating - The report maintains a "Strong Buy" rating for Weitai Medical-B (02235.HK) [1] Core Views - The company recently announced a positive earnings forecast for 2025, projecting revenue of no less than 650 million yuan, representing a year-on-year growth of approximately 88.1%, and achieving a net profit of no less than 38 million yuan, reversing a loss of 63 million yuan in the same period last year [1] - Revenue growth is primarily driven by strong performance in core products, particularly Continuous Glucose Monitoring (CGM) systems, and significant expansion in overseas markets [6] - The company has successfully entered multiple countries with its LinX CGM system, leading to substantial international revenue growth [6] - The company is expected to continue high growth in overseas markets in 2026, with recent approvals in populous countries like India and Brazil [6] - The closed-loop artificial pancreas is anticipated to receive approval in 2026, which will enhance the company's diabetes management product portfolio [6] - The target market capitalization is set at 5.9 billion HKD, corresponding to a target price of 14.0 HKD per share, based on a 4x PS valuation for the main business [6] Financial Summary - For the fiscal years 2024A to 2027E, the projected total revenue is as follows: - 2024A: 346 million yuan - 2025E: 651 million yuan - 2026E: 882 million yuan - 2027E: 1,161 million yuan - Year-on-year growth rates for total revenue are projected at 36.5%, 88.3%, 35.6%, and 31.6% respectively [1][7] - The net profit forecast for the same period is: - 2024A: -63 million yuan - 2025E: 38 million yuan - 2026E: 93 million yuan - 2027E: 152 million yuan - Year-on-year growth rates for net profit are projected at 49.5%, 160.7%, 143.2%, and 63.5% respectively [1][7] - The company’s earnings per share (EPS) is expected to improve from -0.15 yuan in 2024A to 0.36 yuan in 2027E [1][7]